-
Brean Murray Initiates Idenix At Sell, $3 PT
Friday, June 17, 2011 - 7:38am | 27Brean Murray Carret & Company has initiated coverage on Idenix Pharmaceuticals (NASDAQ: IDIX) with a Sell rating and $3 price target.
-
Brean Murray Initiates Achillion Pharmaceuticals At Buy, $9 PT
Friday, June 17, 2011 - 7:37am | 27Brean Murray Carret & Company has initiated coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Buy rating and $9 price target.
-
Brean Murray Initiates Anadys Pharmaceuticals At Hold
Friday, June 17, 2011 - 7:34am | 24Brean Murray Carret & Company has initiated coverage on Anadys Pharmaceuticals (NASDAQ: ANDS) with a Hold rating.
-
GELA and Celgene Announce Collaboration to Evaluate Potential ofREVLIMID for Major Study in Follicular Lymphoma
Friday, June 17, 2011 - 7:33am | 118Groupe d'Etude des Lymphomes de l'Adulte and Celgene International Sarl (Nasdaq: CELG) today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID (lenalidomide)/rituximab combination regimen in patients with newly diagnosed...
-
Brean Murray Initiates Inhibitex At Buy, $6 PT
Friday, June 17, 2011 - 7:33am | 26Brean Murray Carret & Company has initiated coverage on Inhibitex (NASDAQ: INHX) with a Buy rating and $6 price target.
-
Brean Murray Initiates Pharmasset At Buy, $174 PT
Friday, June 17, 2011 - 7:32am | 26Brean Murray Carret & Company has initiated coverage on Pharmasset (NASDAQ: VRUS) with a Buy rating and $174 price target.
-
J.P. Morgan Upgrades Rating, Raises PT To $45 On ITMN
Friday, June 17, 2011 - 7:29am | 201J.P. Morgan is upgrading its rating from Neutral to Overweight and is raising its price target from $38 to $45 on InterMune (NASDAQ: ITMN) as the stock shifts back to fundamentals. According to J.P. Morgan, “ITMN shares have defined SMid cap biotech volatility over the past year driven by US and...
-
Brean Murray Lowers PT On Allos Therapeutics To $6
Friday, June 17, 2011 - 7:22am | 29Brean Murray Carret & Company has lowered the price target on Allos Therapeutics (NASDAQ: ALTH) from $9 to $6 and maintains its Buy rating.
-
Piper Jaffray Lowers PT On MBLX To $5
Friday, June 17, 2011 - 7:20am | 137Piper Jaffray is loweing its price target on Metabolix (NASDAQ: MBLX) but is maintaining an Underweight rating on the stock. Says Piper Jaffray, in its report, “We maintain our Underweight rating on shares of MBLX following a series of conversations with 8 of the company's 10 customers. We...
-
Trading in Regeneron Common Stock Halted for FDA Review
Friday, June 17, 2011 - 7:06am | 108Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that NASDAQ has halted trading of the company's common stock today. The Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration is meeting today to discuss the company's Biologics License Application for...
-
Bank of America Reiterates Neutral and PT of $39 on Cubist Pharmaceuticals
Friday, June 17, 2011 - 6:27am | 123Bank of America reiterated its Neutral rating on Cubist Pharmaceuticals (NASDAQ: CBST). In a research report published today, Bank of America states, "We rate CBST shares Neutral and believe the stock is mostly fairly valued. A major overhang was recently lifted when Cubist settled its Cubicin...
-
BMC Reiterates Buy on Allos Therapeutics
Friday, June 17, 2011 - 6:19am | 51BMC reiterated its Buy rating on Allos Therapeutics (NASDAQ: ALTH). At the same time, BMC left its rating unchanged at $6 after the company's new drug, Istodax, was given a PTCL approval. On Thursday, Allos added 8.65% to its value to close the day at $2.01.
-
Piper Jaffray Lowers PT On Metabolix To $5
Friday, June 17, 2011 - 6:13am | 26Piper Jaffray has lowered the price target on Metabolix (NASDAQ: MBLX) from $7 to $5 and maintains its Underweight rating.
-
JP Morgan Upgrades InterMune To Overweight, Raises PT To $45
Friday, June 17, 2011 - 6:12am | 27JP Morgan has upgraded InterMune (NASDAQ: ITMN) from Neutral to Overweight and has raised the price target from $38 to $45.
-
High-Flying Breakout Plays For 6/17
Thursday, June 16, 2011 - 9:59pm | 157Crazy day in the market today, but there are a lot of stocks testing that infamous 200-day moving average, including Apple (AAPL), Catepillar (CAT), and many others, not to mention the S&P 500 which was tested perfectly today. So there is a good chance we'll see stocks move much higher tomorrow...